Lexeo Therapeutics Inc (NASDAQ: LXEO) on Tuesday, soared 0.84% from the previous trading day, before settling in for the closing price of $8.29. Within the past 52 weeks, LXEO’s price has moved between $5.77 and $22.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 19.69% annually for the last half of the decade. The company achieved an average annual earnings per share of 74.84%. With a float of $23.81 million, this company’s outstanding shares have now reached $33.06 million.
In an organization with 58 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Lexeo Therapeutics Inc (LXEO) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Lexeo Therapeutics Inc is 28.00%, while institutional ownership is 73.91%. The most recent insider transaction that took place on Dec 10 ’24, was worth 20,600. Before that another transaction happened on Nov 25 ’24, when Company’s Director bought 15,000 for $6.99, making the entire transaction worth $104,852. This insider now owns 30,627 shares in total.
Lexeo Therapeutics Inc (LXEO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 74.84% per share during the next fiscal year.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
Lexeo Therapeutics Inc (LXEO) is currently performing well based on its current performance indicators. A quick ratio of 5.95 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.84, a number that is poised to hit -0.81 in the next quarter and is forecasted to reach -3.01 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Let’s dig in a bit further. During the last 5-days, its volume was 0.44 million. That was better than the volume of 0.25 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 72.35%. Additionally, its Average True Range was 0.76.
During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 32.95%, which indicates a significant decrease from 87.21% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 98.03% in the past 14 days, which was higher than the 87.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.21, while its 200-day Moving Average is $12.18. However, in the short run, Lexeo Therapeutics Inc’s stock first resistance to watch stands at $8.62. Second resistance stands at $8.88. The third major resistance level sits at $9.21. If the price goes on to break the first support level at $8.03, it is likely to go to the next support level at $7.70. Assuming the price breaks the second support level, the third support level stands at $7.44.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats
Market capitalization of the company is 276.43 million based on 33,066K outstanding shares. Right now, sales total 0 K and income totals -66,390 K. The company made 0 K in profit during its latest quarter, and -29,490 K in sales during its previous quarter.
